Skip to content

Mitochondria Inborn Errors of Metabolism and ANT Defects in Mitochondria Diseases

Investigation of the Nature and Prevalence of Mitochondria Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00786539
Enrollment
18
Registered
2008-11-06
Start date
2006-10-31
Completion date
2015-05-31
Last updated
2022-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitochondrial Disease

Keywords

mitochondrial

Brief summary

The objective of this research protocol is to continue investigation of the nature and prevalence of mitochondria disease and to aid patients and health care providers in the understanding of these complex disorders. This research study brings together many clinical sub-specialists to address the etiology of these disorders and to develop more effective approaches for their diagnoses and more reliable prognoses.

Detailed description

The non-invasive device named Diffuse Optical Spectroscopy developed at the Beckman Laser Institute is to be used to measure various physiological parameters. Since mitochondria produce most of the energy necessary for cellular function, their efficacy is most important for systems with a high energy demand like the brain, heart, skeletal muscle, kidney, liver, and endocrine tissues. As a result, mitochondria diseases usually manifest as complex, multi-organ disorders, requiring multispecialty investigations.

Interventions

Sponsors

Beckman Laser Institute University of California Irvine
CollaboratorOTHER
University of California, Irvine
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female all ages group with diagnosis of mitochondrial disorder

Exclusion criteria

* Subjects with visual, auditory and/or neurological problems known to result from toxic or environmental effects

Design outcomes

Primary

MeasureTime frame
Symptoms of Mitochondrial diseasesUp to 12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026